A clinical study on adefovir dipivoxil treatment for chronic hepatitis B patients with cirrhosis after partial splenic embolization

Objective To evaluate the efficacy of adefovir dipivoxil treatment for chronic hepatitis B patients with cirrhosis after partial splenic embolization.Methods Forty one chronic hepatitis B patients with cirrhosis after partial splenic embolization were randomly divided into two groups,the experimental group: twenty one patients treated with 10 mg of ADV per day;the control group: twenty patients treated with normal hepatoprotection.During the course of treatment,serum levels of ALT,AST,ALB,TBil,HBeAg,HBV DNA,PC-Ⅲ,IV-C,HA and Child-Pugh scores of the two groups were checked,compared and analyzed.Results Index including ALT,AST,ALB,TBil,PC-III,IV-C and HA in the experimental group were superior to that in the control group.The difference of negtivity rate of HBV DNA(11 in the experimental group and only 1 in the control group) and seroconversion rate of HBeAg/HBeAb(4 in the experimental group and only 1 in the control group) were statistically significant(P0.05).According to their liver function,9 patients of the experimental group belonged to Child-Pugh A,10 belonged to Child-Pugh B,the other 2 belonged to Child-Pugh C.While 6 patients of the control group belonged to Child-Pugh A,7 belonged to Child-Pugh B,the other 7 were Child-Pugh C,and the difference between the two groups was statistically significant.No drug related renal function impairment and other adverse reactions were found during the adefovir dipivoxil treatment.Conclusions Partial splenic embolization is a safe and effective therapy for hypersplenism in cirrhosis,but it can not prevent the aggravation of chronic hepatitis B patients with cirrhosis.Adefovir is a long-term efficient and safe drug for those patients.